Noerr assists M.M.Warburg in successful capital increase by co.don AG

Noerr has advised M.M.Warburg & CO (AG & Co.) Kommanditgesellschaft auf Aktien as the sole underwriter in a cash capital increase with subscription rights by stock corporation co.don Aktiengesellschaft. co.don AG is a specialist in cell cultivation for the regenerative treatment of articular cartilage defects.

During the subscription offer and subsequent private placement, the company placed 2,549,839 new shares at a placement price of €2.30. The issue proceeds come to approximately €5.9 million and are intended to secure the liquidity needed by the company over the next twelve months. In connection with the capital increase, co.don AG’s main shareholder, equity house Bauerfeind Beteiligungsgesellschaft mbH, undertook to provide equity and loan capital, acquiring 900,000 new shares at a total subscription price of €2,070,000.00, and providing a shareholder loan.

Hamburg-based capital markets expert and Noerr partner Stephan Schulz coordinated the transaction. Noerr’s capital markets team has repeatedly advised M.M.Warburg on capital markets transactions, most recently on the capital increase of Epigenomics AG.

Advisors to M.M.Warburg: Noerr LLP

Dr Stephan Schulz (Hamburg, lead), Dr Laurenz Wieneke (Frankfurt, Capital Markets), Simone Schönen (Hamburg, Restructuring), Evelyn Schulz (Dresden, Pharmaceutical Law)

Associates: Dr Jan Hoffmann Linhard, Dr Anca David (both Hamburg, Capital Markets), Susann Jahn (Dresden, Pharmaceutical Law), Philippa Peters (Hamburg, Restructuring)